JP2019508044A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019508044A5 JP2019508044A5 JP2018546653A JP2018546653A JP2019508044A5 JP 2019508044 A5 JP2019508044 A5 JP 2019508044A5 JP 2018546653 A JP2018546653 A JP 2018546653A JP 2018546653 A JP2018546653 A JP 2018546653A JP 2019508044 A5 JP2019508044 A5 JP 2019508044A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- recombinant nucleic
- acid vector
- sequence
- recombinant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 150000007523 nucleic acids Chemical class 0.000 claims 35
- 206010028980 Neoplasm Diseases 0.000 claims 20
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 claims 18
- 201000011510 cancer Diseases 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 14
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 claims 12
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 12
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 12
- 241000700605 Viruses Species 0.000 claims 12
- 230000004936 stimulating effect Effects 0.000 claims 8
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 6
- 102000037978 Immune checkpoint receptors Human genes 0.000 claims 5
- 108091008028 Immune checkpoint receptors Proteins 0.000 claims 5
- 102100022339 Integrin alpha-L Human genes 0.000 claims 5
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 5
- 239000003446 ligand Substances 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 4
- 241000701161 unidentified adenovirus Species 0.000 claims 4
- 108091026890 Coding region Proteins 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 230000002132 lysosomal effect Effects 0.000 claims 2
- 230000010076 replication Effects 0.000 claims 2
- 230000006044 T cell activation Effects 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 238000004873 anchoring Methods 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662310551P | 2016-03-18 | 2016-03-18 | |
| US62/310,551 | 2016-03-18 | ||
| US201662313596P | 2016-03-25 | 2016-03-25 | |
| US62/313,596 | 2016-03-25 | ||
| PCT/US2017/023117 WO2017161360A2 (en) | 2016-03-18 | 2017-03-20 | Multimodal vector for dendritic cell infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019508044A JP2019508044A (ja) | 2019-03-28 |
| JP2019508044A5 true JP2019508044A5 (OSRAM) | 2020-04-16 |
Family
ID=59850551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018546653A Pending JP2019508044A (ja) | 2016-03-18 | 2017-03-20 | 樹状細胞感染のための多モードベクター |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20210198689A1 (OSRAM) |
| EP (1) | EP3430148A4 (OSRAM) |
| JP (1) | JP2019508044A (OSRAM) |
| KR (1) | KR20180118198A (OSRAM) |
| CN (1) | CN109312364A (OSRAM) |
| AU (1) | AU2017233072B2 (OSRAM) |
| CA (1) | CA3016389A1 (OSRAM) |
| IL (1) | IL261812A (OSRAM) |
| MX (1) | MX2018011306A (OSRAM) |
| SG (1) | SG11201808058PA (OSRAM) |
| WO (1) | WO2017161360A2 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201414021D0 (en) | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| US11000559B2 (en) | 2015-04-30 | 2021-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein |
| CN108351917B (zh) | 2015-08-25 | 2022-03-08 | 南托米克斯有限责任公司 | 用于高精度识别变体的系统和方法 |
| MY193281A (en) | 2015-12-17 | 2022-09-30 | Psioxus Therapeutics Ltd | Group b adenovirus encoding an anti-tcr-complex antibody or fragment |
| EP3478312A4 (en) | 2016-06-30 | 2020-07-29 | Nant Holdings IP, LLC | NANT CANCER VACCINE |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| JP2019532621A (ja) | 2016-08-29 | 2019-11-14 | サイオクサス セラピューティクス リミテッド | 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥ）で武装したアデノウイルス |
| LT3630143T (lt) | 2017-06-01 | 2023-09-25 | Akamis Bio Limited | Onkolitinis virusas ir būdas |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| US11823773B2 (en) | 2018-04-13 | 2023-11-21 | Nant Holdings Ip, Llc | Nant cancer vaccine strategies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4409097B2 (ja) * | 1998-12-09 | 2010-02-03 | アメリカ合衆国 | 複数の共刺激分子を発現する組換えベクターおよびその利用 |
| JP4588296B2 (ja) * | 2001-04-05 | 2010-11-24 | ジョンズ・ホプキンス・ユニバーシティ | キメラワクチン |
| EP1441759A2 (de) * | 2001-11-09 | 2004-08-04 | MediGene Aktiengesellschaft | Zelluläre impfstoffe mit adjuvanzien |
| CN1761757A (zh) * | 2003-01-07 | 2006-04-19 | 香港大学 | 用血管抑制素协同加强腺伴随病毒介导的b7.1免疫接种以根除扩散的肝转移性肿瘤 |
| CN101124327A (zh) * | 2003-10-08 | 2008-02-13 | 圣诺菲·帕斯图尔公司 | 经修饰的cea/b7载体 |
| JP2008535868A (ja) * | 2005-04-14 | 2008-09-04 | ザ ユニバーシティー オブ クイーンズランド | 免疫調節組成物およびそのための使用 |
| US20130243731A1 (en) * | 2010-09-24 | 2013-09-19 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti-ctla-4 antibodies |
| HUE037829T2 (hu) * | 2011-08-31 | 2018-09-28 | St Jude Childrens Res Hospital | Eljárások és készítmények lizoszomális exocitózis aktivitás mértékének detektálására és alkamazási eljárások |
| CN102533859A (zh) * | 2012-01-12 | 2012-07-04 | 中国人民解放军第二军医大学 | 携带可诱导性共刺激分子基因的腺病毒载体及其构建方法与应用 |
| EP3587455A1 (en) * | 2012-10-23 | 2020-01-01 | Emory University | Gm-csf and il-4 conjugates, compositions, and methods related thereto |
| MY196581A (en) * | 2013-11-01 | 2023-04-19 | Pfizer | Vectors for Expression of Prostate-Associated Antigens |
| KR102395820B1 (ko) * | 2013-11-05 | 2022-05-09 | 버베리안 노딕 에이/에스 | 종양 항원을 발현하는 폭스바이러스 및 면역 관문 저해제의 길항제 및/또는 효현제를 구비하는 암을 치료하기 위한 복합제 치료제 |
| JP7060324B2 (ja) * | 2013-12-20 | 2022-04-26 | ザ・ブロード・インスティテュート・インコーポレイテッド | ネオ抗原ワクチンによる併用療法 |
| ES2963718T3 (es) * | 2014-01-21 | 2024-04-01 | Novartis Ag | Capacidad presentadora de antígenos de células CAR-T potenciada mediante introducción conjunta de moléculas co-estimuladoras |
| GB201406608D0 (en) * | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| NZ725459A (en) * | 2014-05-13 | 2023-04-28 | Bavarian Nordic As | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
-
2017
- 2017-03-20 MX MX2018011306A patent/MX2018011306A/es unknown
- 2017-03-20 SG SG11201808058PA patent/SG11201808058PA/en unknown
- 2017-03-20 AU AU2017233072A patent/AU2017233072B2/en not_active Ceased
- 2017-03-20 EP EP17767693.9A patent/EP3430148A4/en not_active Withdrawn
- 2017-03-20 US US16/081,014 patent/US20210198689A1/en not_active Abandoned
- 2017-03-20 WO PCT/US2017/023117 patent/WO2017161360A2/en not_active Ceased
- 2017-03-20 CA CA3016389A patent/CA3016389A1/en not_active Abandoned
- 2017-03-20 JP JP2018546653A patent/JP2019508044A/ja active Pending
- 2017-03-20 CN CN201780017523.9A patent/CN109312364A/zh active Pending
- 2017-03-20 KR KR1020187028404A patent/KR20180118198A/ko not_active Ceased
-
2018
- 2018-09-16 IL IL261812A patent/IL261812A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019508044A5 (OSRAM) | ||
| Hollingsworth et al. | Turning the corner on therapeutic cancer vaccines | |
| Cui et al. | Liposome-polycation-DNA (LPD) particle as a carrier and adjuvant for protein-based vaccines: therapeutic effect against cervical cancer | |
| Xiao et al. | CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy | |
| JP2019176869A5 (OSRAM) | ||
| Li et al. | The future of human DNA vaccines | |
| Qiu et al. | Cytomegalovirus-based vaccine expressing a modified tumor antigen induces potent tumor-specific CD8+ T-cell response and protects mice from melanoma | |
| US20180000912A1 (en) | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity | |
| JP2018508567A5 (OSRAM) | ||
| JP2014523406A5 (OSRAM) | ||
| JP2019524773A (ja) | 樹状細胞のトランスフェクション及びその方法 | |
| WO2017161360A4 (en) | Multimodal vector for dendritic cell infection | |
| JP2017538401A5 (OSRAM) | ||
| Lin et al. | Boosting with recombinant vaccinia increases HPV-16 E7-Specific T cell precursor frequencies and antitumor effects of HPV-16 E7-expressing Sindbis virus replicon particles | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| Pilla et al. | Methods for improving the immunogenicity and efficacy of cancer vaccines | |
| Bonaldo et al. | Recombinant yellow fever vaccine virus 17D expressing simian immunodeficiency virus SIVmac239 gag induces SIV-specific CD8+ T-cell responses in rhesus macaques | |
| JP2015524788A5 (OSRAM) | ||
| Garrod et al. | DNA vaccines encoding membrane‐bound or secreted forms of heat shock protein 70 exhibit improved potency | |
| Bellone et al. | Advances in dendritic cell-based therapeutic vaccines for cervical cancer | |
| CN112867501A (zh) | 新的癌抗原和方法 | |
| Zhu et al. | Design and evaluation of a multi-epitope DNA vaccine against HPV16 | |
| JP2016525498A5 (OSRAM) | ||
| CN110234358A (zh) | 多病毒特异性的t细胞免疫疗法 | |
| JP2015518716A5 (OSRAM) |